National Science Foundation

Remedium Bio is a Boston-based gene therapy company dedicated to developing curative treatments for a variety of debilitating conditions. The company employs a unique approach that combines established technologies in innovative ways to address well-defined disease mechanisms. By modularly applying these proven technologies, Remedium Bio focuses on creating localized and targeted therapies centered on clinically validated molecules and pathways. Its pipeline includes leading gene therapy candidates in multiple fields, such as rheumatology, endocrinology, and neurology, aimed at providing effective treatments for a range of immune, age-related, and metabolic disorders.

GENASSIST is a genetics company that provides assisted reproductive technology genetic consultation and testing services.

Protabit develops protein engineering technology, combining computational modeling with high-throughput screening and directed evolution. This enables the exploration of diverse protein sequences for novel proteins, serving industrial, agricultural, and healthcare sectors.

EzraBio is a biotechnology company focused on enhancing ribosome profiling for researchers across various biological samples. The company specializes in RNA adenylation technology, which facilitates efficient and rapid cDNA library construction. By offering streamlined services that encompass sample preparation and deep sequencing, EzraBio aims to simplify the ribosome profiling process. This innovative approach allows medical professionals to uncover hidden coding potential, analyze translational responses, identify tumor-associated antigens, and advance mRNA therapeutics. Through its cutting-edge solutions, EzraBio supports researchers in their quest to deepen understanding of complex biological mechanisms.

Canomiks offers a genomics, bioinformatics, and AI-driven platform that empowers companies in functional food, dietary supplements, and skincare sectors to create safe and effective products. Its long-term goal is to make 'food as medicine' a reality.

Acrigen Biosciences is focused on advancing gene editing technologies to enhance the safety and efficiency of CRISPR-Cas based systems. Founded in 2019 and headquartered in Berkeley, California, the company develops precision gene editing solutions aimed at producing effective and safe in vivo drug therapies for various diseases. Acrigen's innovations include Acro proteins that regulate the CRISPR-Cas gene editing process, along with a bioinformatics discovery software platform designed to identify suitable CRISPR systems for human therapeutic applications. By improving anti-CRISPR proteins and optimizing genetic therapies, Acrigen aims to contribute significantly to the field of medicine and the treatment of debilitating conditions.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Soil Culture Solutions, LLC, founded in 2014 and based in Tampa, Florida, specializes in innovative genetic alteration technology. The company focuses on developing citrus trees using CRISPR editing techniques to enhance their resistance to severe diseases that threaten the citrus industry. Soil Culture Solutions holds exclusive licenses to patents from community universities, enabling it to employ precision breeding methods to effectively combat these critical infections in citrus crops.

Sequegenics is a technology company that specializes in genetic analysis through its fully automated cloud platform. The company has developed a novel approach utilizing augmented low-pass long-read next-generation sequencing (NGS) to identify structural variants and other complex types of genetic variations. By processing long-read NGS raw data, Sequegenics enables clients to efficiently minimize the time and cost associated with variant calling, while also enhancing turnaround time and scalability. This innovative platform supports researchers and healthcare professionals in their efforts to better understand genetic variations, ultimately contributing to advancements in genomic medicine.

Kodikaz Therapeutic Solutions develops a genomic transfer delivery platform for RNA and DNA delivery vectors, aiming to move beyond conventional cancer therapies toward durable cures through targeted gene transfer. Its Zip-Code technology is a cell-specific delivery system derived from an endogenous human mechanism, designed to avoid the challenges of viral delivery and to be applicable across multiple cell types. The company translates cell-recognition and genomic integration mechanisms identified in human cancers into practical therapies, generating both in vitro and in vivo data in oncology to support the development of cell-targeted gene transfer technologies into curative treatments. Applications include cancers such as pancreatic cancer, multiple myeloma, and colorectal cancer, and the platform supports collaborations to help clients develop cell-specific gene transfer approaches.

Ancilia Biosciences is a biotechnology company focused on developing engineered bacterial therapies aimed at treating diseases associated with the microbiome. The company specializes in creating virus-resistant live bacterial products that modulate the human microbiome, specifically targeting the viral components of the gut microbiome. By concentrating on enhancing healthy gut bacteria and their predatory phages, Ancilia develops therapeutic strains that can effectively combat chronic diseases in the fields of immunology and oncology. Additionally, the company is pioneering a new class of live biotherapeutics that allow for the precise targeting of phages or viruses known to induce lysis, thereby advancing treatment options in microbiome-related health conditions.

Founded in 2020, Stellate DNA specializes in developing proprietary DNA donor technology for synthesizing and producing single-strand DNA donors. Headquartered in Cambridge, Massachusetts.

Founded in 2021 and based in South San Francisco, California, Tacit Therapeutics develops RNA-targeted treatments aimed at repairing mutated genes. The company innovates by repurposing existing human cell components to create broadly applicable, non-immunogenic gene modification methods.

IngateyGen is an agricultural biotechnology company focused on developing hypoallergenic and allergen-reduced peanuts and allergen-free peanut butter. Using proprietary technologies in genomics, proteomics, plant tissue culture, and plant propagation, the company aims to create peanut varieties and consumer products that reduce allergens and improve safety for individuals with peanut sensitivities, while pursuing scalable agricultural solutions for the food industry.

Talus Bio is a biotechnology company specializing in drug discovery. It focuses on developing therapies targeting challenging cancer transcription factors using its proprietary MARMOT platform, which integrates functional proteomics, automated biology, machine learning, AI, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics.

Founded in 2018, Ansa Biotechnologies develops an innovative DNA synthesis technology based on enzymes. This novel approach aims to accelerate biological research and engineering by producing gene-length oligonucleotides more efficiently than traditional chemical methods.

NeyroblastGX is a biotechnology company based in Murrieta, California, founded in 2020. It specializes in developing theranostic products aimed at treating neurodegenerative and infectious diseases. The company's innovative product portfolio includes a blood-based biomarker diagnostic for Alzheimer's, genetically engineered dendritic cells designed to target custom-made human organoids for drug screening, and an oral supplement that enhances protective immunity. Through its comprehensive range of diagnostics, drugs, and therapies, NeyroblastGX is committed to providing effective solutions for patients facing life-threatening conditions.

Founded in 2016, Cobio Diagnostics is a biotechnology company based in Golden, Colorado. It specializes in developing diagnostics for bacterial identification and phenotypic antibiotic resistance testing using a phage-based immunoassay. This enables healthcare providers to make quicker and more informed decisions about antibiotic use.

CasTag Biosciences is a biotechnology company that specializes in cell biology and regenerative medicine, with a focus on enhancing the speed of endogenous protein analysis. The company develops Adeno-associated virus kits that leverage a two-vector, clustered regularly interspaced short palindromic repeats-based gene editing technique known as homology-independent universal genome engineering. This innovative approach enables researchers to modify entire panels of proteins within cells and tissues, facilitating the study of novel genes across various experimental models. By providing advanced tools for protein analysis, CasTag Biosciences aims to accelerate scientific discovery and enhance understanding in the field of genetics.

Cornerstone Genomics, established in 2017 and based in Frederick, Maryland, specializes in providing expert guidance on the application of genomic tools in human disease research, biomedicine, veterinary sciences, and wildlife conservation. The company operates a biotechnology platform that houses proprietary DNA and protein sequence databases, along with applications designed to meticulously filter, annotate, and predict the functional impact of genetic variants. This precision enables researchers to accurately identify disease-causing genetic changes, facilitating the development of targeted therapies and gene therapies for inherited diseases.

Jupiter Therapeutics is a biotechnology company specializing in the development of cell-membrane-based therapeutics. It employs cell engineering techniques to create customized vesicles aimed at advancing immuno-oncology and gene therapy. By leveraging a synthetic biology approach, Jupiter Therapeutics facilitates the rapid design and synthesis of a diverse pipeline of therapeutic assets that address critical areas such as cancer and autoimmunity. The company allows medical researchers to utilize insights from cell-membrane studies to enhance the effectiveness of CAR T-cells and bi-specific antibodies, thereby contributing to innovative treatments in the biotherapeutics field.

GRO Biosciences employs computational protein design and synthetic biology to enhance protein therapeutics. It has developed multiple genomically recoded bacterial strains capable of incorporating non-standard amino acids into proteins, resulting in improved potency, stability, and targeted delivery. The company focuses on developing advanced treatments for diabetes, growth disorders, and autoimmunity.

Acrigen Biosciences is focused on advancing gene editing technologies to enhance the safety and efficiency of CRISPR-Cas based systems. Founded in 2019 and headquartered in Berkeley, California, the company develops precision gene editing solutions aimed at producing effective and safe in vivo drug therapies for various diseases. Acrigen's innovations include Acro proteins that regulate the CRISPR-Cas gene editing process, along with a bioinformatics discovery software platform designed to identify suitable CRISPR systems for human therapeutic applications. By improving anti-CRISPR proteins and optimizing genetic therapies, Acrigen aims to contribute significantly to the field of medicine and the treatment of debilitating conditions.

Inherent Biosciences is a molecular diagnostics company focused on transforming the traditional trial and error approach in medicine. The company leverages its innovative epigenetic medicine platform to address various health challenges by identifying gene dysregulation and its associated pathways. By translating biological insights into actionable information, Inherent Biosciences aims to enhance treatment strategies for conditions such as pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. This approach not only guides healthcare professionals in managing complex diseases but also seeks to provide personalized insights that empower patients in their health journeys.

A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

Plastomics is a biotechnology company focused on chloroplast genetic engineering to enhance crop yields and nutritional quality. Its technology platform enables precise insertion of beneficial traits into chloroplasts, reducing cross-pollination and shortening breeding timelines. The company employs gene stacking and rapid breeding approaches to develop biotech crops with a broader set of traits, addressing industry challenges in seed development. Plastomics' approach is applicable across multiple crops and trait areas, supporting commercial trait expression while aiming to lower production costs. Founded in 2016 and headquartered in Saint Louis, Missouri.

A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

Protabit develops protein engineering technology, combining computational modeling with high-throughput screening and directed evolution. This enables the exploration of diverse protein sequences for novel proteins, serving industrial, agricultural, and healthcare sectors.

Inso Biosciences is an early-stage biotechnology company that develops microfluidic hardware platforms for genomic sample handling. The company's patented microfluidic technology enables high-efficiency processing of cellular material and the separation and isolation of cellular components, supporting genomic analysis and DNA sequencing workflows. Its platform aims to improve long-read DNA extraction, multiomic sample processing, and pathogen surveillance, enabling healthcare and biotech organizations to perform biological sample preparation with greater efficiency and accuracy.

LEAH Laboratories specializes in developing innovative gene-editing technologies aimed at treating cancer in dogs, particularly B-cell lymphoma. The company utilizes precision gene editing to reprogram T immune cells with Chimeric Antigen Receptors (CAR), creating CAR T cells that can specifically target and eliminate cancerous cells while minimizing off-target effects commonly associated with traditional chemotherapy. By harnessing the natural capabilities of the canine immune system, LEAH Laboratories provides a novel approach to cancer treatment, offering hope to pet owners and veterinarians in their fight against this challenging disease. Based in the United States, LEAH Labs is committed to advancing medical therapies for canine health.

Inso Biosciences is an early-stage biotechnology company that develops microfluidic hardware platforms for genomic sample handling. The company's patented microfluidic technology enables high-efficiency processing of cellular material and the separation and isolation of cellular components, supporting genomic analysis and DNA sequencing workflows. Its platform aims to improve long-read DNA extraction, multiomic sample processing, and pathogen surveillance, enabling healthcare and biotech organizations to perform biological sample preparation with greater efficiency and accuracy.

Yesse Technologies is a biotechnology company focused on developing an innovative genetic biosensing platform that digitizes the sense of smell. The company utilizes advanced nanotechnology and the biology of real noses to create a unique solution involving genetically modified super sniffer mice, which contribute to a live, human nose-on-a-chip. This technology aims to identify and catalog every conceivable odor, from fragrances used in perfumery to those linked with various diseases. By merging molecular biology, genetic manipulation, and olfaction, Yesse Technologies is positioned to transform odor detection and identification, providing valuable insights across various fields.

Parse Biosciences is a biotechnology company specializing in single-cell analysis and sequencing solutions. Founded in 2018 and based in Seattle, Washington, the company focuses on developing innovative technologies that simplify the sequencing process for researchers. By employing combinatorial cDNA barcoding directly within cells, Parse Biosciences eliminates the necessity for complex and costly microfluidic instruments. This technology allows for the fixing, freezing, and storage of samples, enabling researchers to conduct experiments with samples collected on different dates in a single run. This capability enhances sample handling and minimizes errors, ultimately improving the accuracy of results. The company aims to increase gene detection in individual cells while addressing common challenges associated with single-cell sequencing, thereby advancing research in various scientific fields.

Design Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Solana Beach, California, focused on developing innovative therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company specializes in a novel class of small-molecule gene-targeted chimera therapeutics known as GeneTACTM molecules, which aim to modify disease progression by addressing the root causes of these conditions. Its lead program targets Friedreich’s ataxia, while additional efforts are directed toward conditions such as Fuchs endothelial corneal dystrophy and other degenerative diseases like Fragile X syndrome and myotonic dystrophy. Since its incorporation in 2017, Design Therapeutics has been dedicated to advancing its therapeutic candidates to potentially transform treatment options for patients suffering from these inherited disorders.

Founded in 2018, Ansa Biotechnologies develops an innovative DNA synthesis technology based on enzymes. This novel approach aims to accelerate biological research and engineering by producing gene-length oligonucleotides more efficiently than traditional chemical methods.

Kytopen Corp., founded in 2017, develops proprietary Flowfect™ technology for non-viral delivery of molecules into hard-to-transfect immune cells. Its platform combines microfluidics and automation to facilitate efficient cell engineering.

IngateyGen is an agricultural biotechnology company focused on developing hypoallergenic and allergen-reduced peanuts and allergen-free peanut butter. Using proprietary technologies in genomics, proteomics, plant tissue culture, and plant propagation, the company aims to create peanut varieties and consumer products that reduce allergens and improve safety for individuals with peanut sensitivities, while pursuing scalable agricultural solutions for the food industry.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

GenEdit Inc., established in 2016 and headquartered in Berkeley, California, specializes in developing innovative genome editing tools. The company's core technology is CRISPR/Cas9, which enables precise therapeutic gene editing. GenEdit has further advanced this field by creating the NanoGalaxy™ platform, a proprietary non-viral delivery system that efficiently transports CRISPR/Cas9 to target tissues, overcoming previous delivery challenges. This platform systematically screens a library of nanoparticles to ensure safer and more effective delivery, making therapeutic gene editing easier, faster, and more accurate than traditional methods. GenEdit's ultimate goal is to facilitate the cure of previously incurable genetic diseases by providing physicians with powerful tools for gene therapy.

GRO Biosciences employs computational protein design and synthetic biology to enhance protein therapeutics. It has developed multiple genomically recoded bacterial strains capable of incorporating non-standard amino acids into proteins, resulting in improved potency, stability, and targeted delivery. The company focuses on developing advanced treatments for diabetes, growth disorders, and autoimmunity.

Rumi Scientific is a biotechnology company focused on accelerating the discovery of therapeutics for central nervous system and genetic brain disorders. It has developed an AI-enhanced organoid-like platform that replicates human brain development in vitro, using gene-edited disease models and multicellular self-organization to create defined diseased embryonic tissues. The platform enables high-throughput drug screening and candidate prioritization to identify effective treatments for neurodegenerative and other genetic conditions. By integrating synthetic human embryology with data-driven analysis, the company aims to streamline preclinical drug development and expand options for disorders that currently lack cures.

Soil Culture Solutions, LLC, founded in 2014 and based in Tampa, Florida, specializes in innovative genetic alteration technology. The company focuses on developing citrus trees using CRISPR editing techniques to enhance their resistance to severe diseases that threaten the citrus industry. Soil Culture Solutions holds exclusive licenses to patents from community universities, enabling it to employ precision breeding methods to effectively combat these critical infections in citrus crops.

Cornerstone Genomics, established in 2017 and based in Frederick, Maryland, specializes in providing expert guidance on the application of genomic tools in human disease research, biomedicine, veterinary sciences, and wildlife conservation. The company operates a biotechnology platform that houses proprietary DNA and protein sequence databases, along with applications designed to meticulously filter, annotate, and predict the functional impact of genetic variants. This precision enables researchers to accurately identify disease-causing genetic changes, facilitating the development of targeted therapies and gene therapies for inherited diseases.

BioInfoExperts specializes in comprehensive molecular surveillance services aimed at understanding infectious disease dynamics and monitoring pathogens. The company provides a range of services, including genomic sequencing, extraction of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA), and advanced data analytics. Additionally, BioInfoExperts offers cloud-based data visualizations, facilitating efficient research and development of diagnostic tests for various infectious diseases. With a focus on supporting laboratory services, the company enables clients to enhance their capabilities in pathogen surveillance and analysis.

Parabricks is a developer of high-performance genomic analysis software that utilizes GPU acceleration and machine learning to process next-generation sequencing data. The company's innovative technology allows for the analysis of an entire human genome in under an hour, drastically reducing the time required for genomic processing from days to minutes. This capability not only enhances throughput for healthcare facilities but also enables cost-effective genomic analysis, whether conducted in the cloud or on-premise servers. By facilitating personalized treatment based on genomic variations, Parabricks is poised to transform healthcare practices, making rapid and precise genomic insights accessible for patient care.

Novome Biotechnologies, Inc. is a biotechnology company specializing in the engineering of gut bacteria to create innovative therapies for chronic diseases. Established in 2015 and located in South San Francisco, California, Novome has developed a pioneering platform for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs). This platform allows for the precise delivery of therapeutic activities aimed at treating conditions such as hyperoxaluria, with a focus on creating a bacterial strain that can degrade oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology capabilities to explore additional therapeutic indications, aiming to improve long-term health outcomes for patients through its living therapeutics.

A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

Mission Bio develops and delivers tools for studying cellular heterogeneity in human health and life science research. Its flagship product is the Tapestri Platform, a single-cell platform that detects DNA and protein changes, enabling precise detection of heterogeneity in disease progression and treatment response. The company's solutions are primarily applied in oncology, including blood cancers and solid tumors.

Parabricks is a developer of high-performance genomic analysis software that utilizes GPU acceleration and machine learning to process next-generation sequencing data. The company's innovative technology allows for the analysis of an entire human genome in under an hour, drastically reducing the time required for genomic processing from days to minutes. This capability not only enhances throughput for healthcare facilities but also enables cost-effective genomic analysis, whether conducted in the cloud or on-premise servers. By facilitating personalized treatment based on genomic variations, Parabricks is poised to transform healthcare practices, making rapid and precise genomic insights accessible for patient care.

Kytopen Corp., founded in 2017, develops proprietary Flowfect™ technology for non-viral delivery of molecules into hard-to-transfect immune cells. Its platform combines microfluidics and automation to facilitate efficient cell engineering.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

Yesse Technologies is a biotechnology company focused on developing an innovative genetic biosensing platform that digitizes the sense of smell. The company utilizes advanced nanotechnology and the biology of real noses to create a unique solution involving genetically modified super sniffer mice, which contribute to a live, human nose-on-a-chip. This technology aims to identify and catalog every conceivable odor, from fragrances used in perfumery to those linked with various diseases. By merging molecular biology, genetic manipulation, and olfaction, Yesse Technologies is positioned to transform odor detection and identification, providing valuable insights across various fields.

CrossLife Technologies is a life science company focused on developing and commercializing molecular diagnostics for both infectious and non-communicable diseases. The firm specializes in creating diagnostic tools that utilize nucleic acid and DNA technologies to detect a wide range of infectious pathogens, including HIV, malaria, chikungunya, and influenza. Their innovative approach allows for direct detection of these pathogens from various sample types without the need for sample preparation, polymerase chain reaction, or specialized instrumentation. By advancing these diagnostic technologies, CrossLife Technologies aims to reduce suffering and improve health outcomes for patients.

Inscent is a technology development, gene discovery, and functional genomics company that identified novel molecules to control insect pests. Key areas of interest include the prevention of disease transmission to humans and the development of environmentally friendly products for public health, agricultural, domestic, and industrial applications.

Navipoint Genomics is a bioinformatics analysis software developer headquartered in Chicago, Illinois, and founded in 2015. The company specializes in the analysis of entire human genomes, providing tools that enhance the speed and efficiency of large-scale genomic analysis. Its software facilitates the transfer and examination of full human genomes, significantly reducing analysis time. Additionally, Navipoint Genomics develops a pipeline that enables the investigation of gene expression changes and the detection of fusion transcripts at the whole-transcriptome level. This capability allows clients to achieve improved reporting quality, characterized by high confidence values and fewer false negatives in their genomic analyses.

enEvolv, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in engineering and licensing microorganisms such as bacteria, yeast, and algae for diverse applications across industries including specialty chemicals, food, energy, personal care, and pharmaceuticals. Established in 2011, the company focuses on developing cost-effective and sustainable solutions to meet the growing global demand for critical resources driven by population growth and increased economic prosperity. enEvolv collaborates with various organizations to create novel microorganisms and enhance existing strains to boost production yields and improve product quality. Utilizing a proprietary genome engineering platform based on advanced techniques developed at Harvard, enEvolv accelerates microbial evolution to enable precise genomic edits, offering significant advantages in speed, cost, and engineering capabilities. As of March 2020, enEvolv operates as a subsidiary of Zymergen, Inc.

Varigen Biosciences is developing new technologies for capturing and expressing natural product pathways. Learn about our DNAtrap™ custom cloning service which delivers verified clones of your DNA target (up to 100 kb) in just 10 days at http://varigenbiosciences.com/dnatrap-custom-cloning-service/. Learn about how our BigDNA™ metagenomics libraries can revolutionize natural product discovery at http://varigenbiosciences.com/products/.

Parabricks is a developer of high-performance genomic analysis software that utilizes GPU acceleration and machine learning to process next-generation sequencing data. The company's innovative technology allows for the analysis of an entire human genome in under an hour, drastically reducing the time required for genomic processing from days to minutes. This capability not only enhances throughput for healthcare facilities but also enables cost-effective genomic analysis, whether conducted in the cloud or on-premise servers. By facilitating personalized treatment based on genomic variations, Parabricks is poised to transform healthcare practices, making rapid and precise genomic insights accessible for patient care.

BioInfoExperts specializes in comprehensive molecular surveillance services aimed at understanding infectious disease dynamics and monitoring pathogens. The company provides a range of services, including genomic sequencing, extraction of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA), and advanced data analytics. Additionally, BioInfoExperts offers cloud-based data visualizations, facilitating efficient research and development of diagnostic tests for various infectious diseases. With a focus on supporting laboratory services, the company enables clients to enhance their capabilities in pathogen surveillance and analysis.

Novome Biotechnologies, Inc. is a biotechnology company specializing in the engineering of gut bacteria to create innovative therapies for chronic diseases. Established in 2015 and located in South San Francisco, California, Novome has developed a pioneering platform for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs). This platform allows for the precise delivery of therapeutic activities aimed at treating conditions such as hyperoxaluria, with a focus on creating a bacterial strain that can degrade oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology capabilities to explore additional therapeutic indications, aiming to improve long-term health outcomes for patients through its living therapeutics.

IngateyGen is an agricultural biotechnology company focused on developing hypoallergenic and allergen-reduced peanuts and allergen-free peanut butter. Using proprietary technologies in genomics, proteomics, plant tissue culture, and plant propagation, the company aims to create peanut varieties and consumer products that reduce allergens and improve safety for individuals with peanut sensitivities, while pursuing scalable agricultural solutions for the food industry.

Modular Genetics designs and develops engineered microorganisms that synthesize chemicals from renewable raw materials, such as sugar. The company uses an automated gene engineering system to create new products, with a focus on sustainable chemistry. It aims to accelerate product development, reduce costs, and enable simultaneous development of multiple products. Founded in 2000 and based in Woburn, Massachusetts.

T3S Technologies is a biotechnology company focused on producing proteins from bacteria and enabling the expression and optimization of difficult-to-express recombinant proteins. Founded in 2015 and based in Salt Lake City, Utah, it applies expertise in genetics and biochemistry together with proprietary technologies to engineer bacterial cells for efficient protein production. The platform targets challenging protein products to support researchers and biopharmaceutical development in protein-based research and potential therapies.

Mission Bio develops and delivers tools for studying cellular heterogeneity in human health and life science research. Its flagship product is the Tapestri Platform, a single-cell platform that detects DNA and protein changes, enabling precise detection of heterogeneity in disease progression and treatment response. The company's solutions are primarily applied in oncology, including blood cancers and solid tumors.

Serotiny, Inc. is a biotechnology company based in San Francisco, California, focused on the design and development of multi-domain proteins and therapies aimed at treating cancers and genetic disorders. Founded in 2014, Serotiny leverages a unique platform that integrates synthetic biology with advanced informatics to facilitate the rational design of proteins. The company specializes in creating therapeutic proteins for CAR T-cell therapies and other cellular therapies. By harmonizing computational protein design, high-throughput cellular assays, and next-generation sequencing, Serotiny employs a cross-disciplinary approach that incorporates expertise from immunology, machine learning, software engineering, and bioinformatics. This innovative methodology enables the development of gene and cell therapies with improved safety and efficacy through novel control mechanisms and engineered functionalities.

Protabit develops protein engineering technology, combining computational modeling with high-throughput screening and directed evolution. This enables the exploration of diverse protein sequences for novel proteins, serving industrial, agricultural, and healthcare sectors.

Aperiomics is a biotechnology company based in Sterling, Virginia, specializing in pathogen detection services across animal screening, agricultural testing, and human diagnostics industries. Founded in 2013, the company uses advanced genomics and informatics technologies to detect viral, bacterial, fungal, and parasitic pathogens through a single test. Aperiomics employs sequencing technologies and Bayesian statistics to analyze blood, tissue, and stool samples sent by customers. The company's unique approach, supported by the National Science Foundation, involves Deep Shotgun Metagenomic Sequencing and a comprehensive database of over 37,000 microbes. This enables medical professionals to identify infections that other tests may miss, leading to more accurate diagnoses and improved clinical outcomes for patients who have often been ill for extended periods without a clear cause.

Epicrop Technologies, Inc. is a biotechnology company based in Lincoln, Nebraska, founded in 2013. The company specializes in developing innovative epigenetic technology aimed at enhancing crop yields and crop development. Epicrop's technology focuses on improving abiotic stress tolerance across all plant species, providing farmers with the tools to increase productivity while maintaining lower crop prices. In addition to its core technology, Epicrop also offers support services that assist in optimizing crop production, thereby contributing to sustainable agricultural practices.

Knudra Transgenics, LLC, founded in 2009 and located in Murray, Utah, specializes in the research, development, and production of deoxyribonucleic acid (DNA) mixes and plasmids tailored for the biomedical industry. The company provides a custom transgenics production service, focusing on organisms such as Caenorhabditis elegans (C. elegans). Knudra operates as a subsidiary of NemaMetrix, Inc., and offers a cloud-based genome engineering platform that enables biotechnologists to test the genome compositions of various organisms by injecting external reagents.

Mission Bio develops and delivers tools for studying cellular heterogeneity in human health and life science research. Its flagship product is the Tapestri Platform, a single-cell platform that detects DNA and protein changes, enabling precise detection of heterogeneity in disease progression and treatment response. The company's solutions are primarily applied in oncology, including blood cancers and solid tumors.

GlobalBio specializes in therapeutic antibody engineering. The company, which was founded in 2014 with funds from the National Science Foundation, is based in Brookline, Massachusetts.

Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

enEvolv, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in engineering and licensing microorganisms such as bacteria, yeast, and algae for diverse applications across industries including specialty chemicals, food, energy, personal care, and pharmaceuticals. Established in 2011, the company focuses on developing cost-effective and sustainable solutions to meet the growing global demand for critical resources driven by population growth and increased economic prosperity. enEvolv collaborates with various organizations to create novel microorganisms and enhance existing strains to boost production yields and improve product quality. Utilizing a proprietary genome engineering platform based on advanced techniques developed at Harvard, enEvolv accelerates microbial evolution to enable precise genomic edits, offering significant advantages in speed, cost, and engineering capabilities. As of March 2020, enEvolv operates as a subsidiary of Zymergen, Inc.

TeselaGen Biotechnology, established in 2011 and headquartered in San Francisco, specializes in DNA design and assembly tools for biological research. The company provides a cloud-based solution enabling combinatorial gene design and editing, which includes tools for visualizing, editing, and annotating genetic sequences, constructing novel gene constructs, optimizing assembly protocols, and validating design variants.

TeselaGen Biotechnology, established in 2011 and headquartered in San Francisco, specializes in DNA design and assembly tools for biological research. The company provides a cloud-based solution enabling combinatorial gene design and editing, which includes tools for visualizing, editing, and annotating genetic sequences, constructing novel gene constructs, optimizing assembly protocols, and validating design variants.

TeselaGen Biotechnology, established in 2011 and headquartered in San Francisco, specializes in DNA design and assembly tools for biological research. The company provides a cloud-based solution enabling combinatorial gene design and editing, which includes tools for visualizing, editing, and annotating genetic sequences, constructing novel gene constructs, optimizing assembly protocols, and validating design variants.

Insilicom provides advanced next-generation sequencing data analysis solutions for cancer research biomarker discovery. The company was founded in 2013 and is headquartered in Tallahassee, Florida.

Advirna is a biotechnology company developing innovative solutions for delivering polynucleotides into living cells. It specializes in self-deliverable RNA interference (RNAi) technology, enabling efficient gene knockdown both ex vivo and in vivo.

Aperiomics is a biotechnology company based in Sterling, Virginia, specializing in pathogen detection services across animal screening, agricultural testing, and human diagnostics industries. Founded in 2013, the company uses advanced genomics and informatics technologies to detect viral, bacterial, fungal, and parasitic pathogens through a single test. Aperiomics employs sequencing technologies and Bayesian statistics to analyze blood, tissue, and stool samples sent by customers. The company's unique approach, supported by the National Science Foundation, involves Deep Shotgun Metagenomic Sequencing and a comprehensive database of over 37,000 microbes. This enables medical professionals to identify infections that other tests may miss, leading to more accurate diagnoses and improved clinical outcomes for patients who have often been ill for extended periods without a clear cause.

Parabon NanoLabs Inc. is a biotechnology company based in Reston, Virginia, specializing in the development of innovative nanopharmaceuticals and advanced forensic products. Utilizing a cutting-edge nanoscale development platform, the company designs multi-functional macromolecules aimed at treating various types of cancer, including brain, lung, and breast cancers. Additionally, Parabon NanoLabs develops and licenses its macromolecules for diverse applications, such as nano-sensors for bioweapons defense, DNA biometrics, and consumer product enhancements. The company's team comprises experts in fields like bioinformatics, oncology, chemistry, and computer science, which allows it to create next-generation therapeutics and forensic tools by harnessing the power of DNA. As a small business recognized by the U.S. Small Business Administration, Parabon NanoLabs has received multiple grants and contracts through the Small Business Innovation Research and Small Business Technology Transfer programs.

Modular Genetics designs and develops engineered microorganisms that synthesize chemicals from renewable raw materials, such as sugar. The company uses an automated gene engineering system to create new products, with a focus on sustainable chemistry. It aims to accelerate product development, reduce costs, and enable simultaneous development of multiple products. Founded in 2000 and based in Woburn, Massachusetts.

Protabit develops protein engineering technology, combining computational modeling with high-throughput screening and directed evolution. This enables the exploration of diverse protein sequences for novel proteins, serving industrial, agricultural, and healthcare sectors.

Molecular Assemblies, Inc. is a San Diego-based company that specializes in enzymatic DNA synthesis technology, aimed at creating DNA-based products across various industries. Founded in 2013, the company has developed a proprietary method that allows for the reliable, affordable, and sustainable production of long, high-quality, sequence-specific DNA. This innovative technology is designed to support advancements in industrial synthetic biology, personalized therapeutics, precision diagnostics, and has potential applications in information storage and nanotechnology. With a strong executive and scientific team, as well as a robust intellectual property portfolio, Molecular Assemblies is positioned to enhance the capabilities of researchers and contribute to the evolution of DNA-based applications.

The J. Craig Venter Institute is a prominent organization in genomic research, formed in 2006 through the merger of several legacy institutions, including The Institute for Genomic Research and The Center for the Advancement of Genomics. With over 400 scientists and staff, the institute operates from locations in Rockville, Maryland, and San Diego, California, encompassing more than 250,000 square feet of laboratory space. The institute has been at the forefront of genomic advancements for over two decades, initiated by Dr. J. Craig Venter and his teams, who pioneered techniques such as expressed sequence tags and contributed to the sequencing of the first free-living organism, Haemophilus influenzae. The institute's research spans a wide array of fields including genomics medicine, infectious diseases, mammalian genomics, microbial and environmental genomics, and synthetic biology. Recent projects include the sequencing of the first diploid human genome, global ocean sampling expeditions, and the analysis of various infectious disease agents. The institute aims to enhance human health and environmental understanding through its innovative research efforts.

Protabit develops protein engineering technology, combining computational modeling with high-throughput screening and directed evolution. This enables the exploration of diverse protein sequences for novel proteins, serving industrial, agricultural, and healthcare sectors.

Inscent is a technology development, gene discovery, and functional genomics company that identified novel molecules to control insect pests. Key areas of interest include the prevention of disease transmission to humans and the development of environmentally friendly products for public health, agricultural, domestic, and industrial applications.

Caribou Biosciences develops cellular engineering solutions based on CRISPR technologies, offering a gene editing platform with applications in human therapeutics, disease modeling, genomics research, and agricultural biotechnology.

enEvolv, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in engineering and licensing microorganisms such as bacteria, yeast, and algae for diverse applications across industries including specialty chemicals, food, energy, personal care, and pharmaceuticals. Established in 2011, the company focuses on developing cost-effective and sustainable solutions to meet the growing global demand for critical resources driven by population growth and increased economic prosperity. enEvolv collaborates with various organizations to create novel microorganisms and enhance existing strains to boost production yields and improve product quality. Utilizing a proprietary genome engineering platform based on advanced techniques developed at Harvard, enEvolv accelerates microbial evolution to enable precise genomic edits, offering significant advantages in speed, cost, and engineering capabilities. As of March 2020, enEvolv operates as a subsidiary of Zymergen, Inc.

Knudra Transgenics, LLC, founded in 2009 and located in Murray, Utah, specializes in the research, development, and production of deoxyribonucleic acid (DNA) mixes and plasmids tailored for the biomedical industry. The company provides a custom transgenics production service, focusing on organisms such as Caenorhabditis elegans (C. elegans). Knudra operates as a subsidiary of NemaMetrix, Inc., and offers a cloud-based genome engineering platform that enables biotechnologists to test the genome compositions of various organisms by injecting external reagents.

Primordial Genetics Inc. is a biotechnology company based in San Diego, California, founded in 2011. The company specializes in developing microbes and enzymes for pharmaceutical and industrial manufacturing, as well as agriculture. It utilizes whole-genome synthetic biology tools to create production organisms and industrial enzymes. One of its key innovations is the Function Generator, a combinatorial gain-of-function genetic technology that enhances the tolerances, productivities, and growth characteristics of microbial organisms. This technology supports the renewable production of chemicals, fuels, pharmaceuticals, and other commercially valuable compounds. Primordial Genetics' solutions are applicable across various industries, including therapeutic protein production, industrial enzyme development, novel protein discovery, and the creation of renewable fuels and chemicals.

Digital World Biology develops and sells mobile applications and instructional materials that allow students to conduct molecular biology research. The apps can be used by elementary school students to work with DNA structures and molecules. They bring bioinformatics out of the lab and into the classroom. The company also provides professional development for college instructors and school teachers, as a genomics consulting service.

Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Da Yu Protein Sciences is a research driven biotechnology company developing technologies and services for drug discovery and the bioprocessing industry. Their client base includes biopharmaceutical companies, pharmaceutical companies, and research organizations pursuing drug discovery and development.

Modular Genetics designs and develops engineered microorganisms that synthesize chemicals from renewable raw materials, such as sugar. The company uses an automated gene engineering system to create new products, with a focus on sustainable chemistry. It aims to accelerate product development, reduce costs, and enable simultaneous development of multiple products. Founded in 2000 and based in Woburn, Massachusetts.

Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Cambrian Genomics specializes in manufacturing hardware for laser printing DNA sequences. They serve both academic and industrial researchers who require high-quality, sequence-verified DNA strands for their studies or applications, capitalizing on the existing global market valued at over $1 billion annually.

Akonni Biosystems, Inc. is a biotechnology company specializing in molecular diagnostics, focusing on the development and manufacture of integrated systems for clinical and life science research markets. Founded in 2003 and headquartered in Frederick, Maryland, the company offers a range of products, including the TruDiagnosis point-of-care testing platform, which allows healthcare professionals to analyze infectious diseases effectively. Its product lineup features TruTip kits for DNA and RNA extraction, TruArray tests for multiplexed molecular diagnostics from various clinical samples, and various MDx instrument platforms such as microarray readers and thermal cyclers. The company’s technologies are particularly relevant for diagnosing infectious diseases, pharmacogenomics, oncology, Alzheimer’s, and cardiovascular conditions, addressing complex health issues including multi-drug-resistant infections.

InnoGenomics Technologies specializes in genetic testing solutions, offering a comprehensive range of services that includes DNA quantification, STR genotyping, genotyping and gene expression assays. The company has developed a patented technology that is versatile and applicable in various fields such as forensic identification, missing person investigations, and the establishment of relationships and ancestral ethnic-geographic connections. Additionally, InnoGenomics provides biological sample research and development, validation services, and training to support its genetic testing capabilities. This combination of innovative technology and diverse service offerings positions InnoGenomics as a key player in the genetic testing industry.

TeselaGen Biotechnology, established in 2011 and headquartered in San Francisco, specializes in DNA design and assembly tools for biological research. The company provides a cloud-based solution enabling combinatorial gene design and editing, which includes tools for visualizing, editing, and annotating genetic sequences, constructing novel gene constructs, optimizing assembly protocols, and validating design variants.

Knudra Transgenics, LLC, founded in 2009 and located in Murray, Utah, specializes in the research, development, and production of deoxyribonucleic acid (DNA) mixes and plasmids tailored for the biomedical industry. The company provides a custom transgenics production service, focusing on organisms such as Caenorhabditis elegans (C. elegans). Knudra operates as a subsidiary of NemaMetrix, Inc., and offers a cloud-based genome engineering platform that enables biotechnologists to test the genome compositions of various organisms by injecting external reagents.